Features of infections due to klebsiella pneumoniae carbapenemase-producing escherichia coli: Emergence of sequence type 131

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 224-231

  Kim, Young Ah ^a,b   Qureshi, Zubair A ^a   Adams Haduch, Jennifer M ^a   Park, Yoon Soo ^a,c   Shutt, Kathleen A ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b National Health Insurance Corporation   (South Korea)

^c Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CARBAPENEMASE; CEFEPIME; CEFUROXIME; CIPROFLOXACIN; COLISTIMETHATE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; NITROFURANTOIN; SULFAMETHOXAZOLE; SULTAMICILLIN; TIGECYCLINE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; ESCHERICHIA COLI; GENE SEQUENCE; HUMAN; INFECTION SENSITIVITY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; CROSS INFECTION; ELECTROPHORESIS, GEL, PULSED-FIELD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PLASMIDS; UNITED STATES;

EID: 84864136493     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis387     Document Type: Article

References (38)

1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228-36.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113(Suppl 1A):5S-13S. (Pubitemid 34756640)
3. Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972-5. (Pubitemid 46452064)
4. Landman D, Urban C, Backer M, et al. Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol 2010; 48:4604-7.
5. Urban C, Bradford PA, Tuckman M, et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase β-lactamases associated with long-term care facilities. Clin Infect Dis 2008; 46:e127-30. (Pubitemid 351706793)
6. Robledo IE, Aquino EE, Vazquez GJ. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob Agents Chemother 2011; 55:2968-70.
7. Sidjabat HE, Silveira FP, Potoski BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009; 49:1736-8.
8. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1-14.
9. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35:316-21.
10. Johnson JR, Urban C, Weissman SJ, et al. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum β-lactamase-producing E. coli from the United States (2000-2009). Antimicrob Agents Chemother 2012; 56:2364-70.
11. Morris D, Boyle F, Ludden C, et al. Production of KPC-2 carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone. Antimicrob Agents Chemother 2011; 55: 4935-6.
12. Naas T, Cuzon G, Gaillot O, Courcol R, Nordmann P. When carbapenem-hydrolyzing β-lactamase KPC meets Escherichia coli ST131 in France. Antimicrob Agents Chemother 2011; 55:4933-4.
13. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723-5. (Pubitemid 47295515)
14. Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type β-lactamase by use of a boronic acid compound. J Clin Microbiol 2008; 46:4083-6.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Wayne, PA, 2011.
16. Sidjabat HE, Paterson DL, Qureshi ZA, et al. Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clin Infect Dis 2009; 48:739-44.
17. Sidjabat HE, Paterson DL, Adams-Haduch JM, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother 2009; 53:4733-9.
18. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66:4555-8.
19. Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 2006; 60:1136-51.
20. Ribot EM, Fair MA, Gautom R, et al. Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet. Foodborne Pathog Dis 2006; 3:59-67.
21. Doi Y, Paterson DL, Adams-Haduch JM, et al. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase. Antimicrob Agents Chemother 2009; 53:3159-61.
22. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181:261-72. (Pubitemid 30049057)
23. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis 2008; 14:195-200. (Pubitemid 351213667)
24. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61:273-81.
25. Mushtaq S, Irfan S, Sarma JB, et al. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J Antimicrob Chemother 2011; 66:2002-5.
26. Cortes P, Blanc V, Mora A, et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl Environ Microbiol 2010; 76:2799-805.
27. Naseer U, Haldorsen B, Tofteland S, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. Apmis 2009; 117:526-36.
28. Oteo J, Diestra K, Juan C, et al. Extended-spectrum β- lactamaseproducing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents 2009; 34:173-6.
29. Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011; 70:507-11.
30. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-9. (Pubitemid 41418336)
31. Rodriguez-Bano J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin Infect Dis 2006; 42:935-7.
32. Peirano G, Richardson D, Nigrin J, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extendedspectrum-β- lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother 2010; 54:1327-30.
33. Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y. Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009; 63:72-9.
34. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286-94.
35. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46:3900-5.
36. Goren MG, Carmeli Y, Schwaber MJ, Chmelnitsky I, Schechner V, Navon-Venezia S. Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient. Emerg Infect Dis 2010; 16:1014-7.
37. Richter SN, Frasson I, Bergo C, Parisi S, Cavallaro A, Palu G. Transfer of KPC-2 carbapenemase from Klebsiella pneumoniae to Escherichia coli in a patient: first case in Europe. J Clin Microbiol 2011; 49:2040-2.
38. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2010; 54:4112-5.